Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Jun 3;11(1):11734.
doi: 10.1038/s41598-021-91238-8.

Chronic liver disease not a significant comorbid condition for COVID-19

Affiliations
Observational Study

Chronic liver disease not a significant comorbid condition for COVID-19

Jiahao Lin et al. Sci Rep. .

Abstract

To explore the role of chronic liver disease (CLD) in COVID-19. A total of 1439 consecutively hospitalized patients with COVID-19 from one large medical center in the United States from March 16, 2020 to April 23, 2020 were retrospectively identified. Clinical characteristics and outcomes were compared between patients with and without CLD. Postmortem examination of liver in 8 critically ill COVID-19 patients was performed. There was no significant difference in the incidence of CLD between critical and non-critical groups (4.1% vs 2.9%, p = 0.259), or COVID-19 related liver injury between patients with and without CLD (65.7% vs 49.7%, p = 0.065). Postmortem examination of liver demonstrated mild liver injury associated central vein outflow obstruction and minimal to moderate portal lymphocytic infiltrate without evidence of CLD. Patients with CLD were not associated with a higher risk of liver injury or critical/fatal outcomes. CLD was not a significant comorbid condition for COVID-19.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Kaplan–Meier survival curves of (A) overall survival, and (B) time to mechanical ventilation/ICU admission in COVID-19 patients with CLD or without CLD.
Figure 2
Figure 2
Postmortem liver findings in COVID-19. (A), (B) and (C) from patient 5, show minimal (A) to moderate (B) portal lymphocytic infiltrate and central vein outflow obstruction injury (C); (D) from patient 3, shows minimal portal lymphocytic infiltrate and fibrin thrombi; (E) and (F) from patient 7, show extensive central vein outflow obstruction associated with centrilobular necrosis (E) and mild portal lymphocytic infiltrate (F).

Similar articles

Cited by

References

    1. World Health Organization. COVID-19 weekly epidemiological update (accessed 12 November 2020). https://www.who.int/docs/default-source/coronaviruse/situation-reports/2... (2020).
    1. Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and liver. J. Hepatol. 2020;73:1231–1240. doi: 10.1016/j.jhep.2020.06.006. - DOI - PMC - PubMed
    1. Guan W, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur. Respir. J. 2020;55:2000547. doi: 10.1183/13993003.00547-2020. - DOI - PMC - PubMed
    1. Chen T, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ. 2020;368:m1091. doi: 10.1136/bmj.m1091. - DOI - PMC - PubMed
    1. Guan W, et al. China medical treatment expert group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. - DOI - PMC - PubMed

Publication types